502068811 09/20/2012

PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

| SUBMISSION TYPE: | NEW ASSIGNMENT |
|-----------------------|----------------|
| NATURE OF CONVEYANCE: | ASSIGNMENT |

CONVEYING PARTY DATA

| Name | Execution Date |
|-------------------------|----------------|
| Cleveland BioLabs, Inc. | 09/02/2012 |

RECEIVING PARTY DATA

| Name: | The Cleveland Clinic Foundation |
|-----------------|---------------------------------|
| Street Address: | 9500 EUCLID AVENUE |
| City: | CLEVELAND |
| State/Country: | ОНЮ |
| Postal Code: | 44195 |

PROPERTY NUMBERS Total: 1

| Property Type | Number |
|---------------------|----------|
| Application Number: | 12369704 |

CORRESPONDENCE DATA

Fax Number: 3128191910

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 3128191900

Email: rgalant@polsinelli.com

Correspondent Name: Ron Galant, Ph.D.

Address Line 1: Polsinelli Shughart PC

Address Line 2: 161 North Clark Street, Suite 4200

Address Line 4: Chicago, ILLINOIS 60601

ATTORNEY DOCKET NUMBER: 050991.0202.02US

NAME OF SUBMITTER: Ron Galant, Ph.D.

Total Attachments: 1

source=ASSIGNMENT#page1.tif

PATENT REEL: 028994 FRAME: 0456 ICH \$40.00 1236970

WHEREAS, Cleveland BioLabs, Inc., a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 73 High St., Buffalo, NY 14203 (hereinafter, "Assignor"), has an undivided interest in U.S. Patent Application No. 12/369,704, filed on February 11, 2009 and titled METHOD FOR REDUCING THE EFFECTS OF CHEMOTHERAPY USING FLAGELLIN RELATED POLYPEPTIDES (hereinafter, the "Application"); and

WHEREAS, The Cleveland Clinic Foundation, a non-profit corporation organized and existing under the laws of the State of Ohio, together with any successors, assigns and legal representatives thereof (hereinafter, called the "Assignee") is desirous of acquiring the entire right, title and interest, in and to said Application.

NOW, THEREFORE, the Assignor hereby sells, assigns, transfers and conveys unto Assignee the entire right, title and interest of such Assignor in and to said Application, exclusive of any and all other applications related thereto, existing as of even date or hereafter, including divisions, renewals and continuations of the Application, and any and all Letters Patent of the United States which may be granted thereon, and all reissues, reexaminations, and extensions thereof, and all priority rights under all available international agreements, treaties and conventions for the protection of intellectual property in its various forms in every participating country, and all applications for Letters Patent or other grants of protection of proprietary rights including, but not limited to, inventor's certificate, utility model, utility certificate, patent of importation, registration of patent and industrial design registration which may be filed, and which may be granted, upon said inventions in any countries or regions foreign to the United States, and all reissues, renewals and extensions thereof.

IN TESTIMONY WHEREOF, this Assignment is executed by Assignor on the date opposite the signature of Assignor.

Yakov Kogan

CEO, Cleveland BioLabs, Inc.

Date

156555.3